(Reuters) – AstraZeneca said on Friday it had appointed Alexion’s Aradhana Sarin as its new chief financial officer as it shifts existing CFO Marc Dunoyer to a new role leading the U.S.-based drugmaker after the pair’s merger.
AstraZeneca agreed to buy Alexion in December in its largest ever deal, a bet on rare-disease immunology which also includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.
London-listed AstraZeneca said Sarin’s appointment was conditional upon the completion of its $39 billion buyout of Alexion.
Dunoyer will become the U.S. drugmaker’s chief executive officer while also being appointed chief strategy officer at AstraZeneca. He will leave the Anglo-Swedish company’s board but continue to report to CEO Pascal Soriot.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich and Patrick Graham)
